The biotech sector is rapidly growing as more companies focus on clinical research and developing new drugs. Most biotech companies focus on a specific disease or medical condition to solve, which tends to make these stocks risky. The niche nature of the company means you’ll see a huge pay-off if trials are successful, but there are a lot of hurdles to cover.
Biotech companies are setting out to change the world in some way, which makes them popular among speculative investors. Let’s take a look at some of the most successful biotech companies of 2019.
Celgene develops and markets drug treatments for inflammatory disorders and cancer. The company’s flagship product is the drug Revlimid, which is approved for treating multiple myeloma and transfusion-dependent anemias. Celgene topped headlines in early 2019 when the company offered to acquire Bristol-Myers Squibb for $74 billion. The acquisition may help Celgene overcome struggling revenues as its flagship product faces patent expiration.
This pharmaceutical company, headquartered in Delaware, focuses on researching treatments for cancer and arthritis. The company’s flagship product is Jakafi, which is a drug used to treat polycythemia vera. The budding biotech company first began phase three trials of a new medicine this year.
The drug called Itacitinib is designed to treat Chronic Graft-Versus-Host disease. Patient trials with the drug started in February, and the results of those trials have yet to be posted.
This Washington-based company works to develop and market cancer treatment drugs, specifically antibody-drug conjugates. These ADCs use antibodies to target and eliminate cancer cells. Seattle Genetic’s most flagship drug is Adcetris, which helps treat cancer using ADCs. Adcetris is available in over 70 countries.
In January 2019, the company published data from a phase three clinical trial of Adcetris, which was used to treat certain types of Hodgkin Lymphoma. The results of that test appear to show that Adcetris induces “superior clinical activity” when combined with other treatment methods.
The Boston-based Vertex Pharmaceuticals has helped pave the way by streamlining the process of rational drug design strategy. After 30 years in the industry, Vertex has focused on treating inflammatory and autoimmune disorders, cancer, and more. In 2019, the company began testing three cystic fibrosis drug treatments. The late-stage data from clinical trials of those drugs suggest these new treatment combinations may perform well for patients.
About The Author
Kyle Dennis is a Professional Trader and Educator at Raging Bull Trading, a trading program designed to help both new and experienced traders master the stock market. Kyle originally joined Raging Bull Trading as a new student looking to master his skills. Through Raging Bull’s Millionaire Roadmap program, Kyle became the first student in its history to make $1 million in trading profits. Following his success, Kyle Dennis joined Raging Bull Trading as a trader and educator. He offers his specialized program, Biotech Breakouts, through Raging Bull, and is focused on mastering biotech stock trading.